Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group.

Eur Respir J · 2022 · PMC8819469 · PMID 35115337

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Even if the primary end-point was not reached, it is interesting and somewhat surprising to observe a nonsignificant trend in day 90 better overall survival with both anti-IL-6R antibodies.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.